Equities research analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce $5.05 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for Voyager Therapeutics’ earnings. The lowest sales estimate is $1.50 million and the highest is $6.71 million. Voyager Therapeutics posted sales of $2.36 million during the same quarter last year, which suggests a positive year-over-year growth rate of 114%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 21st.

On average, analysts expect that Voyager Therapeutics will report full year sales of $5.05 million for the current fiscal year, with estimates ranging from $4.70 million to $10.49 million. For the next financial year, analysts forecast that the business will post sales of $15.30 million per share, with estimates ranging from $6.00 million to $32.20 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Voyager Therapeutics.

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $31.00 price objective (up previously from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. Canaccord Genuity assumed coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price objective on the stock. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 8th. ValuEngine upgraded shares of Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Raymond James Financial assumed coverage on shares of Voyager Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price target on the stock. Three research analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $26.33.

In other news, insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the completion of the sale, the insider now directly owns 17,157 shares of the company’s stock, valued at $171,570. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 38,430 shares of company stock valued at $562,890 over the last three months. Insiders own 8.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. lifted its stake in Voyager Therapeutics by 0.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock worth $261,000 after acquiring an additional 114 shares during the period. Fiduciary Trust Co. lifted its stake in Voyager Therapeutics by 0.4% in the second quarter. Fiduciary Trust Co. now owns 109,034 shares of the company’s stock worth $977,000 after acquiring an additional 473 shares during the period. Goldman Sachs Group Inc. lifted its stake in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares during the period. California State Teachers Retirement System lifted its stake in Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after acquiring an additional 2,000 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its stake in Voyager Therapeutics by 11.8% in the second quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock worth $334,000 after acquiring an additional 3,939 shares during the period. 35.97% of the stock is owned by institutional investors.

Shares of Voyager Therapeutics (NASDAQ:VYGR) traded down $0.19 during trading hours on Friday, reaching $14.44. 354,976 shares of the company’s stock traded hands, compared to its average volume of 901,072. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $25.99.

WARNING: “Brokerages Anticipate Voyager Therapeutics Inc (VYGR) Will Post Quarterly Sales of $5.05 Million” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/03/brokerages-anticipate-voyager-therapeutics-inc-vygr-will-post-quarterly-sales-of-5-05-million.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.